Analytical Assays
Multiplex analysis
Multiplex immunoassays allow simultaneous detection and quantification of multiple analytes in a single sample from a variety of biological specimens including but not limited to serum, plasma, CSF, cell culture supernatants, sputum.
xMAP Technology has application in serological assays by easy detection of antibodies. A serology assay enables the detection of an antibody (target) with the use of a capture protein antigen attached to the surface of a microsphere. A detection antibody that incorporates a fluorescent label is used to quantify the amount of target antibody present. This assay is useful when serum antibodies need to be measured, such as for the response to a vaccine, allergic reactions, or autoantibody detection.
It combines the efficiency and sensitivity of traditional ELISAs with high through-put capacity, small sample volume,efficiency in terms of time and cost,high reproducibility and sensitivityand analyte quantification over a wide range of concentrations.
Principle of xMAP Technology
Applications:
- Measurement of cytokine/chemokine/inflammatory mediator expression in variety of biological specimens which can be applied for biomarker discovery and Target validation
- Allergy testing
- Single nucleotide polymorphisms (SNPs) testing
- Diagnosis of infectious diseases
- Application areas include inflammation, autoimmune diseases, asthma, obesity/diabetes, neurological disorders, cancer, cardiovascular disease, drug discovery and vaccine development.
Biomarker qualification and validation
- Robust validated technology
- Simultaneous detection and quantification of multiple analytes in a single sample from a variety of biological specimens
- High sensitivity and reproducibility
- High through-put capacity
- Efficiency in terms of time and cost
- Various species
Popular Protein Analytes for Measurement
| No | Plex | Assay Panel | Description |
|---|---|---|---|
| 1 | 41-plex | Human Cytokine/Chemokine Panel I | sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3 ligand, Fractalkine, G-CSF, GM-CSF, GRO, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1α, MIP-1β, PDGF-AA, PDGF-AB/BB, RANTES, TGF-α, TNF-α, TNF-β, VEGF |
| 2 | 29-plex | Human Cytokine/Chemokine Panel II | EGF, G-CSF, GM-CSF, IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-1β, TNF-α, TNF-β, VEGF, Eotaxin/CCL11 |
| 3 | 23-plex | Human Cytokine/Chemokine Panel III | 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin-2, Eotaxin-3, I-309, IL-16, IL-20, IL-21, IL-23, IL-28A, IL-33, LIF, MCP-2, MCP-4, MIP-1d, SCF, SDF-1A+β, TARC, TPO, TRAIL, TSLP |
| 4 | 25-plex | Human Th17 Panel | GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17A, IL-17F, IL-17E/IL-25, IL-21, IL-22, IL-23, IL-27, IL-28A, IL-31, IL-33, MIP-3α/CCL20, TNF-α, TNFβ |
| 5 | 5-plex | Human Diabetes Panel | Insulin, Glucagon, Leptin, GLP-1 (Active), C-Peptide |
| 6 | 11-plex | Human Kidney Injury Panel | Calbindin, Collagen IV, FABP1, GSTα, GSTπ, IP-10, KIM-1, Osteoactivin, Renin, TFF-3, TIMP-1 |
| 7 | 8-plex | Human Src Family Kinase Panel – Phosphoprotein | Blk (Tyr389), Fgr (Tyr412), Fyn (Tyr420), Hck (Tyr411), Lck (Tyr394), Lyn (Tyr397), Src (Tyr419), Yes (Tyr421) |
| 8 | 17-plex | Human Angiogenesis/Growth Factor Panel | Angiopoietin-2, BMP-9, EGF, Endoglin, Endothelin-1, FGF-1, FGF-2, Follistatin, G-CSF, HB-EGF, HGF, IL-8, Leptin, PLGF, VEGF-A, VEGF-C, VEGF-D |
| 9 | 7-plex | DNA Damage/Genotoxicity Panel | ATR (Total), Chk1 (Ser345), Chk2 (Thr68), H2A.X (Ser139), MDM2 (total), p21 (Total), p53 (Ser15) |
| 10 | 6-plex | Human Apolipoprotein Panel | Apo AI, Apo AII, Apo B, Apo CII, Apo CIII, Apo E |
| 11 | 12-plex | Human Bone Metabolism Panel | ACTH, DKK-1, FGF-23, IL-1β, IL-6, Insulin, Leptin, Osteocalcin, OPN – Osteopontin, Osteoprotegerin, PTH, SOST, TNF-α |
| 12 | 9-plex | Human Cancer/ Metastasis Biomarker Panel | DKK-1, GDF-15, NSE, OPG, Osteonectin (SPARC), Periostin, TRAP5, TWEAK, YKL40 |
| 13 | 10-plex | Human Cardiovascular Disease (CVD) Panel 1 | ADAMTS13, D-Dimer, GDF-15, Myoglobin, sICAM-1, MPO, P-selectin, Lipocalin-2/NGAL, sVCAM-1, SAA. |
| 14 | 14-plex | Human Cardiovascular Disease (Acute Phase) Panel 2 | AGP, Haptoglobin, SAP, Adipsin, Human a2, CRP, Fetuin, Fibrinogen, L-Selectin, PF4, vonWillebrand Factor |
| 15 | 24-plex | Human Circulating Cancer Biomarker Panel I | AFP, CEA, CYFRA21-1, FGF-2, HE4, PSA Total, PSA free, HGF, IL-6, IL-8, Leptin, MIF, OPN – Osteopontin, Prolactin, SCF, sFas, sFasL, TGF-α, TNF-α, TRAIL, VEGF, CA125, CA15-3, CA19-9, β-HCG |
| 16 | 5-plex | Human Circulating Cancer Biomarker Panel 2 | Antithrombin III, Complement Factor H, Extracellular Matrix Protein 1, Vitamin D Binding Protein, Vitronectin |
| 17 | 7-plex | Human Early Apoptosis Panel | Akt (Ser473), BAD (Ser112), Bcl-2 (Ser70), Active Caspase 8 (Asp384), Active Caspase 9 (Asp315), JNK (Thr183/Tyr185), p53 (Ser46) |
| 18 | 11-plex | Human Kidney Injury Panel 1 | Calbindin, Collagen IV, FABP1, GSTα, GSTπ, IP-10, KIM-1, Osteoactivin, Renin, TFF-3, TIMP-1 |
| 19 | 7-plex | Human Kidney Injury Panel 2 | α-1-Microglobulin, Albumin, Clusterin, Cystatin C, EGF, Lipocalin-2/NGAL, Osteopontin (OPN) |
| 21 | 13-plex | Human Metabolic Hormone Panel | Amylin (Total), Amylin (Active), C-Peptide, Ghrelin, GIP, GLP-1 (Active), GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNF-α |
| 20 | 9-plex | Human Liver Protein Panel – Metabolism | AFP, ANGPTL3, ANGPTL4, ANGPTL6/AGF, FABP1, FGF-19, FGF-21, FGF-23, HGF |
| 21 | 13-plex | Human Metabolic Hormone Panel | Amylin (Total), Amylin (Active), C-Peptide, Ghrelin, GIP, GLP-1 (Active), GLP-1 (Total), Glucagon, IL-6, Insulin, Leptin, MCP-1, PP, PYY, TNF-α |
| 22 | 14-plex | Human Soluble Cytokine Receptor Panel | sCD30, sEGFR, sgp130, sIL-1RI, sIL-1RII, sIL-2Rα, sIL-4R, sIL-6R, sRAGE, sTNFRI, sTNFRII, sVEGF-R1, sVEGF-R2, sVEGF-R3 |
| 23 | 7-plex | T-Cell Receptor Signaling Panel | CD3ε (pan Tyr), CREB (S133), ERK (Thr185/Tyr187), LAT (pan Tyr), Lck (pan Tyr), Syk (pan Tyr), ZAP-70 (pan Tyr) |
| 24 | 5-plex | Human Neurodegenerative Disease Panel | Human Neurodegenerative Disease Panel |
| 25 | 3-plex | Human Sepsis Panel | FGF-13, Olfactomedin-4 (OLFM-4), MMP-8 |
| 26 | 7-plex | Human Skin Immune Response Panel | Cortisol, HSA, Fibronectin, LPS, Involucrin, Keratin-6, Keratin-1,10 |
| 27 | 13-plex | Human High Sensitivity T Cell Panel | GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p70), IL-13, TNF-α |
| 28 | 7-plex | Total Mitogenesis RTK Panel | EGFR (Total), ErbB2/HER2 (Total), ErbB3/HER3 (Total), ErbB4/HER4 (Total), IR (total), c-Met/HGFR (Total), IGF-1R (Total) |
| 29 | 9-plex | Multi-Pathway Total Cell Signaling Panel | Erk/MAPK 1/2 (Total), Akt (Total), STAT3 (Total), JNK (Total), p70 S6 Kinase (Total), NFκB (Total), STAT5A/B (Total), CREB (Total), p38 (Total) |
| 30 | 5-plex | Human Oxidative Stress Magnetic Bead Panel – Cellular Metabolism Multiplex Assay | Catalase, PRX2, SOD1, SOD2, TRX1 |
ELISA
Flow Cytometry
Western Blot
Biomarker Validation and Qualification
Validation is the process of evaluating the reliability, reproducibility and accuracy of the biomarker across a range of experimental conditions. Qualification process provides an evidentiary link between the biomarker and biological processes/clinical end points.
Following validation and qualification, a biomarker can be used to diagnose the risk, presence and prognosis of a disease in an individual. In evaluating potential drug therapies, a biomarker may be used as a surrogate for a natural endpoint such as survival or irreversible morbidity. If a treatment alters the biomarker, which has a direct connection to improved health, the biomarker serves as a surrogate endpoint for evaluating clinical benefit. Some of the main areas in which molecular biomarkers are used in the drug development process are: early drug development studies, safety studies, proof of concept studies, and molecular profiling.
We offer assay development and validation for prognostic/predictive clinical biomarkers and pathway activation biomarkers:
- Mutliplex immunoassay
- Multiplex nucleic acid testing
- Western Blot
- Clinical Chemistry assays
